EGFR and non-small cell lung carcinoma: Thus, our finding suggests that chemotherapy plus bevacizumab as the first-line treatment had a better curative rate and tolerable adverse reactions in NSCLC patients with brain metastasis, especially in patients with EGFR wild type NSCLC.